MedTrace Logo

The Lighthouse Tenofovir Cohort Study

NCT02381275 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 1500

Last updated 2018-06-07

No results posted yet for this study

Summary

Lighthouse, in cooperation with the University Heidelberg Public Health Institute and the University Köln (Cologne) would like to set up a cohort to study baseline characteristics and long-term clinical outcomes of patients using Tenofovir based Antiretroviral Therapy at the Lighthouse. As of March 2014, patients above 18 years and giving informed consent coming to the Lighthouse to newly initiate ART will be approached to enroll in the cohort.

The results will be disseminated both nationally at the Ministry of Health Technical Working Group (TWG), at the annual Research Dissemination and Best Practices conferences of the College of Medicine and National AIDS Commission as well as internationally. The results will also be written up for publication in appropriate peer-reviewed journals.

Conditions

  • Chronic Renal Disease

Interventions

DRUG

Tenofovir Disoproxil Fumarate

Observe long-term outcomes of patients using Tenofovir based antiretroviral therapy at the Lighthouse Clinics

Sponsors & Collaborators

  • Heidelberg University

    collaborator OTHER

  • Ministry of Health, Malawi

    collaborator OTHER_GOV

  • University of Cologne

    collaborator OTHER

  • Lighthouse Trust

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-08-14
Primary Completion
2018-07-31
Completion
2018-07-31

Countries

  • Malawi

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02381275 on ClinicalTrials.gov